Schneider, B.J., Kalemkerian, G.P., Ramnath, N., Kraut, M.J., Wozniak, A.J., Worden, F.P., Ruckdeschel, J.C., Zhang, X.H., Chen, W. and Gadgeel, S.M. (2010) Phase II Trial of Imatinib Maintenance Therapy after Irinotecan and Cisplatin in Patients with c-Kit-Positive, Extensive-Stage Small-Cell Lung Cancer. Clinical Lung Cancer, 11, 223-227. http://dx.doi.org/10.3816/CLC.2010.n.028

has been cited by the following article:

• TITLE: Missing the Target?—Targeted Therapy in Small Cell Lung Cancer

  AUTHORS: Karin R. Purshouse

  KEYWORDS: Oncology, Small Cell Lung Cancer, Targeted Therapy, Drug Development

  JOURNAL NAME: Advances in Lung Cancer, Vol.3 No.3, August 22, 2014

  ABSTRACT: Small cell lung cancer [SCLC] is a devastating form of cancer, with most patients harbouring extensive disease at diagnosis and survival of less than 5% at five years. Progress in novel therapies has been limited. This specialist review explores current targeted therapy options and potential areas of development.